SYNAGIS 100 mg/ml 1 vial 0,5 ml Andorra - angol - CedimCat (Centre d'Informació de Medicaments de Catalunya)

synagis 100 mg/ml 1 vial 0,5 ml

SYNAGIS 100 mg/ml 1 vial 1 ml Andorra - angol - CedimCat (Centre d'Informació de Medicaments de Catalunya)

synagis 100 mg/ml 1 vial 1 ml

SYNAGIS 100MG INJECTION Malajzia - angol - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synagis 100mg injection

abbvie sdn bhd - palivizumab -

Synagis 100mgml solution for Injection Malajzia - angol - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synagis 100mgml solution for injection

astrazeneca sdn. bhd. - palivizumab -

SYNAGIS SOLUTION FOR INJECTION 100MGML Szingapúr - angol - HSA (Health Sciences Authority)

synagis solution for injection 100mgml

astrazeneca singapore pte ltd - palivizumab - injection, solution - palivizumab 100mg/ml

Synagis 100mg 100 mg Jordánia - angol - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

synagis 100mg 100 mg

مستودع أدوية حسام النمر - hussam al nmer drug store - palivizumab 100 mg - 100 mg

Synagis 50mg 50 mg Jordánia - angol - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

synagis 50mg 50 mg

مستودع أدوية حسام النمر - hussam al nmer drug store - palivizumab 50 mg - 50 mg

SYNADRIN Tablets Írország - angol - HPRA (Health Products Regulatory Authority)

synadrin tablets

hoechst ireland limited - prenylamine - tablets

ABBOSYNAGIS 100 MG Izrael - angol - Ministry of Health

abbosynagis 100 mg

abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

ABBOSYNAGIS 50 MG Izrael - angol - Ministry of Health

abbosynagis 50 mg

abbvie biopharmaceuticals ltd, israel - palivizumab 50 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.